Another biotech is squeezing into the crowded IPO waiting room just in time for the weekend. BlossomHill Therapeutics, a San Diego-based oncology outfit focused on small molecules, has filed paperwork with the Securities and Exchange Commission to publicly offer stock for the first time.
BlossomHill eyes IPO as fertilizer to grow taller in crowded cancer fields
Post navigation
Previous Post
Gene Therapy Partners Aim to Enhance Protein Expression